The potassium current carried by TREK-1 channels in rat cardiac ventricular muscle

Pflugers Arch. 2015 May;467(5):1069-79. doi: 10.1007/s00424-014-1678-9. Epub 2014 Dec 25.

Abstract

We studied the potassium current flowing through TREK-1 channels in rat cardiac ventricular myocytes. We separated the TREK-1 current from other current components by blocking most other channels with a blocker cocktail. We tried to inhibit the TREK-1 current by activating protein kinase A (PKA) with a mixture of forskolin and isobutyl-methylxanthine (IBMX). Activation of PKA blocked an outwardly rectifying current component at membrane potentials positive to -40 mV. At 37 °C, application of forskolin plus IBMX reduced the steady-state outward current measured at positive voltages by about 52 %. Application of the potassium channel blockers quinidine or tetrahexylammonium also reduced the steady-state outward current by about 50 %. Taken together, our results suggest that the increase in temperature from 22 to 37 °C increased the TREK-1 current by a factor of at least 5 and that the average density of the TREK-1 current in rat cardiomyocytes at 37 °C is about 1.5 pA/pF at +30 mV. The contribution of TREK-1 to the action potential was assessed by using a dynamic patch clamp technique. After subtraction of simulated TREK-1 currents, action potential duration at 50 or 90 % repolarisation was increased by about 12 %, indicating that TREK-1 may be functionally important in rat ventricular muscle. During sympathetic stimulation, inhibition of TREK-1 channels via PKA is expected to prolong the action potential primarily in subendocardial myocytes; this may decrease the transmural dispersion of repolarisation and thus may serve to prevent the occurrence of arrhythmias.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Methyl-3-isobutylxanthine / pharmacology
  • Animals
  • Membrane Potentials / drug effects*
  • Membrane Potentials / physiology
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / metabolism*
  • Patch-Clamp Techniques / methods
  • Phosphodiesterase Inhibitors / pharmacology
  • Potassium / metabolism*
  • Potassium Channel Blockers / pharmacology*
  • Potassium Channels, Tandem Pore Domain / metabolism*
  • Rats

Substances

  • Phosphodiesterase Inhibitors
  • Potassium Channel Blockers
  • Potassium Channels, Tandem Pore Domain
  • potassium channel protein TREK-1
  • Potassium
  • 1-Methyl-3-isobutylxanthine